M. Shaheen

发表

Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma

J. Kirkwood, A. Ribas, M. Milhem, 2018, Clinical Trials.

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

Ed S. McCarron, C. Slingluff, K. Lewis, 2021, Journal for ImmunoTherapy of Cancer.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

A. Tolcher, K. Papadopoulos, M. Beeram, 2017, Cancer Chemotherapy and Pharmacology.

Phase II Study of Ifosfamide Plus Daily Oral Etoposide in Previously Treated Ovarian Cancer: A Hoosier Oncology Group (HOG) Study

L. Einhorn, M. Shaheen, K. Look, 2004, American journal of clinical oncology.

Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis.

D. Harron, M. Shaheen, M. Homeida, 1994, Annals of tropical medicine and parasitology.

Stromal cell‐derived factor‐1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and Gαi proteins and enhances engraftment of competitive, repopulating stem cells

H. Broxmeyer, C. Mantel, Younghee Lee, 2003, Journal of leukocyte biology.

310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma

T. Wagner, G. Peoples, A. Berger, 2020, Journal for ImmunoTherapy of Cancer.

Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy: 2423

A. Vinik, R. Pommier, E. Wolin, 2015 .

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma.

R. Murthy, Douglas B. Johnson, P. Hwu, 2021, Cancer discovery.

Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

G. Linette, C. Horak, J. Wolchok, 2017 .

Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis

T. Wagner, G. Peoples, A. Berger, 2020, Cancer medicine.

Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

A. Vinik, B. Mirakhur, R. Pommier, 2018, The oncologist.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

G. Linette, C. Horak, J. Wolchok, 2015, The New England journal of medicine.

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

G. Peoples, A. Berger, J. Sussman, 2021, Melanoma research.

Cytotoxic activity of the titanium alkoxide (OPy)2Ti(4AP)2 against cancer colony forming cells

T. Boyle, R. Hromas, C. Verschraegen, 2012, Investigational New Drugs.

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells

R. Hromas, E. Williamson, J. Nickoloff, 2009, PloS one.

Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance

J. Jeter, S. Sundararajan, M. Shaheen, 2017, Pharmacological research.

304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

Katie M. Campbell, D. Davar, J. Kirkwood, 2020 .

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

G. Linette, C. Horak, J. Wolchok, 2016, The Lancet. Oncology.

Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy.

Tudor I. Oprea, T. Oprea, L. Sklar, 2012, Cancer research.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

J. Desai, E. Rasmussen, M. Carducci, 2018, Investigational New Drugs.

Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.

D. Munn, R. McWilliams, C. Link, 2016 .

Synthetic lethality: exploiting the addiction of cancer to DNA repair.

R. Hromas, J. Nickoloff, M. Shaheen, 2011, Blood.

Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.

G. Linette, C. Horak, J. Wolchok, 2015 .

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

F. Hodi, S. O’Day, T. Guthrie, 2016, Journal of Immunotherapy for Cancer.

Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining

R. Hromas, E. Williamson, J. Nickoloff, 2010, Proceedings of the National Academy of Sciences.

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

V. Sondak, M. Ross, M. Atkins, 2023, The New England journal of medicine.

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

D. Munn, R. McWilliams, R. Kolhe, 2021, Journal for ImmunoTherapy of Cancer.

The Role of PCNA Posttranslational Modifications in Translesion Synthesis

R. Hromas, M. Shaheen, Ilanchezhian Shanmugam, 2010, Journal of nucleic acids.

423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors

M. Burgess, C. Kelly, A. Daud, 2020 .

E. Plimack, M. Sznol, M. Postow, 2017, Cancer treatment reviews.

Metnase/SETMAR: a domesticated primate transposase that enhances DNA repair, replication, and decatenation

R. Hromas, E. Williamson, J. Nickoloff, 2010, Genetica.

1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma

Douglas B. Johnson, I. Puzanov, J. Markowitz, 2020 .

Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial

T. Wagner, G. Peoples, A. Berger, 2022, Cancer Immunology, Immunotherapy.

Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

G. Linette, J. Wolchok, F. Hodi, 2016 .

ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

R. Motzer, J. Hsieh, A. Hussain, 2019, Annals of Oncology.

First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.

M. Carducci, J. Bauman, C. Verschraegen, 2012 .

USP47 regulates a 53BP1-based complex function in DNA DSB repair

R. Hromas, M. Shaheen, Baowei Chen, 2022, bioRxiv.

Ubiquitin-Specific-Processing Protease 47, A Novel 53BP1 regulator

Baowei Chen, M. Shaheen, D. T. Sadideen, 2021 .

O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab

Katie M. Campbell, D. Davar, J. Kirkwood, 2020, Journal of Immunotherapy for Cancer.

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.

R. Motzer, J. Hsieh, Chung-Han Lee, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.

R. Janssen, A. Ribas, G. Daniels, 2018, Journal of Clinical Oncology.

Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study.

P. Hwu, I. Puzanov, S. Swann, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours

K. Papadopoulos, A. Fasolo, A. Naing, 2019, Annals of Oncology.

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.

D. Munn, R. McWilliams, C. Link, 2018 .

950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma

D. Davar, J. Kirkwood, A. Ribas, 2021, Journal for ImmunoTherapy of Cancer.

A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

F. Hodi, T. Guthrie, A. Salama, 2015 .

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.

E. Schmidt, R. Janssen, A. Ribas, 2019, Journal of Clinical Oncology.

A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.

R. Murthy, Douglas B. Johnson, I. Puzanov, 2018 .

Chapter 16 – Cytokine/Receptor Families and Signal Transduction

H. Broxmeyer, M. Shaheen, 2018 .

Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study

A. Vinik, B. Mirakhur, R. Pommier, 2016 .

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

M. Carlino, T. Zaks, C. Robert-Tissot, 2024, The Lancet.

A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.

J. Reeves, A. Tolcher, Dajun Yang, 2023, Journal of Clinical Oncology.

Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)

G. Linette, C. Horak, J. Wolchok, 2016 .

Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

T. Wagner, G. Peoples, A. Berger, 2023, Journal for ImmunoTherapy of Cancer.